195 related articles for article (PubMed ID: 14739059)
1. Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
Gadducci A; Cosio S; Carpi A; Nicolini A; Genazzani AR
Biomed Pharmacother; 2004 Jan; 58(1):24-38. PubMed ID: 14739059
[TBL] [Abstract][Full Text] [Related]
2. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
3. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix.
Takeda M; Sakuragi N; Okamoto K; Todo Y; Minobe S; Nomura E; Negishi H; Oikawa M; Yamamoto R; Fujimoto S
Acta Obstet Gynecol Scand; 2002 May; 81(5):451-7. PubMed ID: 12027820
[TBL] [Abstract][Full Text] [Related]
4. Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
Gadducci A; Tana R; Fanucchi A; Genazzani AR
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S23-6. PubMed ID: 17727924
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen.
Inaba N; Negishi Y; Fukasawa I; Okajima Y; Ota Y; Tanaka K; Matsui H; Iwasaki H; Sudo H; Tanaka N
Tumour Biol; 1995; 16(6):345-52. PubMed ID: 7569681
[TBL] [Abstract][Full Text] [Related]
6. Normalization of abnormal plasma amino acid profile-based indexes in patients with gynecological malignant tumors after curative treatment.
Suzuki Y; Tokinaga-Uchiyama A; Mizushima T; Maruyama Y; Mogami T; Shikata N; Ikeda A; Yamamoto H; Miyagi E
BMC Cancer; 2018 Oct; 18(1):973. PubMed ID: 30314462
[TBL] [Abstract][Full Text] [Related]
7. Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix.
Ferdeghini M; Gadducci A; Annicchiarico C; Prontera C; Malagnino G; Castellani C; Facchini V; Bianchi R
Anticancer Res; 1993; 13(5C):1841-4. PubMed ID: 7505543
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
[TBL] [Abstract][Full Text] [Related]
9. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
[TBL] [Abstract][Full Text] [Related]
10. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
[TBL] [Abstract][Full Text] [Related]
11. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies.
Suzuki M; Ohwada M; Sato I; Nagatomo M
Oncology; 1995; 52(2):128-33. PubMed ID: 7854772
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 serum levels in patients with gynecological tumors.
Scambia G; Testa U; Panici PB; Martucci R; Foti E; Petrini M; Amoroso M; Masciullo V; Peschle C; Mancuso S
Int J Cancer; 1994 May; 57(3):318-23. PubMed ID: 8168990
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of squamous cell carcinoma antigen and ovarian carcinoma antigen (CA 125) in patients with benign and malignant diseases of the uterine cervix.
Gocze PM; Vahrson HW; Freeman DA
Oncology; 1994; 51(5):430-4. PubMed ID: 8052484
[TBL] [Abstract][Full Text] [Related]
14. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients.
Tempfer C; Hefler L; Haeusler G; Reinthaller A; Koelbl H; Zeisler H; Kainz C
Int J Cancer; 1998 Jun; 79(3):241-4. PubMed ID: 9645344
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data.
Ferdeghini M; Gadducci A; Prontera C; Marrai R; Malagnino G; Annicchiarico C; Fioretti P; Bianchi R
Anticancer Res; 1993; 13(3):709-13. PubMed ID: 8317901
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma.
Duk JM; Groenier KH; de Bruijn HW; Hollema H; ten Hoor KA; van der Zee AG; Aalders JG
J Clin Oncol; 1996 Jan; 14(1):111-8. PubMed ID: 8558185
[TBL] [Abstract][Full Text] [Related]
17. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment.
Pras E; Willemse PH; Canrinus AA; de Bruijn HW; Sluiter WJ; ten Hoor KA; Aalders JG; Szabo BG; de Vries EG
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):23-32. PubMed ID: 11777619
[TBL] [Abstract][Full Text] [Related]
18. Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome.
Scambia G; Benedetti Panici ; Foti E; Ferrandina G; Leone FP; Marciano M; Mancuso S
Eur J Cancer; 1996 Feb; 32A(2):259-63. PubMed ID: 8664038
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of serum squamous cell carcinoma antigen in patients with early cervical squamous cell carcinoma].
Li D; Xu XX; Yan DD; Yuan SH; Lou HM
Zhonghua Zhong Liu Za Zhi; 2019 May; 41(5):357-362. PubMed ID: 31137169
[No Abstract] [Full Text] [Related]
20. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers.
Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M
Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
